About Dr. Miao Xiaohui
Dr. Miao Xiaohui (缪晓辉) is a Professor, Doctoral Supervisor, and one of China's leading specialists in infectious disease and viral hepatitis, based at the Department of Infectious Disease, Changhai Hospital, Naval Medical University (Second Military Medical University). With extensive clinical and research experience spanning viral hepatitis B and C, liver cirrhosis, hepatic failure, tropical and travel-related infectious diseases, and emerging infectious diseases, Dr. Miao is recognized as a senior authority in the management of complex infectious conditions at one of China's most distinguished military academic medical centers.
For international patients — expatriates living in Shanghai and medical tourists from regions where infectious disease expertise is limited or where access to the latest antiviral therapies is restricted — Dr. Miao offers a level of clinical depth in the evaluation and management of viral hepatitis, liver disease, and infectious conditions that is rarely available outside major academic infectious disease centers. His particular expertise in chronic hepatitis B and C — conditions that affect hundreds of millions of people in Asia and globally — and in the management of hepatitis-related cirrhosis and its complications makes him an invaluable resource for patients seeking optimal antiviral therapy, liver disease monitoring, and complication management.
Hospital Affiliation: Department of Infectious Disease, Changhai Hospital
Changhai Hospital (长海医霂), affiliated with Naval Medical University, is one of Shanghai's largest and most prestigious academic medical centers. Its Department of Infectious Disease is a high-volume clinical program managing the full spectrum of infectious conditions encountered in a major tertiary referral hospital serving both military and civilian populations, with particular expertise in viral hepatitis, liver disease, and tropical and travel-related infections. The department is equipped with a dedicated viral hepatology clinic, a liver disease monitoring program including transient elastography (FibroScan) for non-invasive liver fibrosis assessment, and a multidisciplinary hepatology team integrating infectious disease, hepatobiliary surgery, interventional radiology, and gastroenterology for comprehensive management of advanced liver disease and its complications.
The department maintains active research collaborations with infectious disease and hepatology centers across China and internationally, and participates in national and international clinical trials of novel antiviral therapies for hepatitis B and C. For international patients, Changhai Hospital offers access to the full range of approved direct-acting antiviral (DAA) therapies for hepatitis C — including pan-genotypic regimens with cure rates exceeding 95% — and the latest nucleos(t)ide analogue therapies for hepatitis B, at costs substantially below those of equivalent treatment in Western healthcare systems.
Clinical Specialties: What Dr. Miao Xiaohui Treats
- Chronic hepatitis B (CHB) — comprehensive evaluation of CHB including HBV DNA quantification, HBeAg/anti-HBe status, liver function assessment, and non-invasive fibrosis staging; initiation and optimization of nucleos(t)ide analogue therapy (tenofovir alafenamide, tenofovir disoproxil fumarate, entecavir); monitoring for HBsAg loss and functional cure; management of HBV reactivation in immunosuppressed patients; coordination with oncology for antiviral prophylaxis during chemotherapy
- Chronic hepatitis C (CHC) — HCV genotyping and pre-treatment assessment; pan-genotypic DAA therapy with sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, or other approved regimens; treatment of DAA-experienced patients with resistance-associated substitutions; management of hepatitis C in patients with advanced cirrhosis, renal impairment, or HIV coinfection; post-SVR surveillance for HCC in patients with advanced fibrosis
- Liver cirrhosis and portal hypertension — non-invasive fibrosis assessment with FibroScan and serum biomarkers; management of cirrhosis complications including ascites, spontaneous bacterial peritonitis (SBP), hepatic encephalopathy, and variceal bleeding; coordination with gastroenterology for endoscopic variceal ligation and TIPS evaluation; hepatorenal syndrome management; liver transplantation evaluation and referral
- Acute and subacute hepatic failure — management of acute liver failure from viral, drug-induced, and autoimmune causes; artificial liver support systems; liver transplantation evaluation and urgent referral coordination
- Tropical and travel-related infectious diseases — diagnosis and management of malaria, dengue fever, typhoid, leptospirosis, brucellosis, and other tropical infections encountered in expatriates and returning travelers; travel medicine consultation and pre-travel vaccination and prophylaxis advice
- HIV/AIDS management — antiretroviral therapy initiation and optimization; management of HIV-related opportunistic infections; HIV and hepatitis B/C coinfection management; coordination with immunology for comprehensive HIV care
- Drug-induced liver injury (DILI) — diagnosis and management of hepatotoxicity from prescription medications, herbal and dietary supplements, and traditional Chinese medicine preparations; causality assessment using RUCAM criteria; management of severe DILI with systemic corticosteroids where indicated
Why International Patients Choose Dr. Miao Xiaohui and Changhai Hospital
International patients — particularly expatriates living in Shanghai and patients from Southeast Asia, the Middle East, and Africa where viral hepatitis is highly prevalent — seek consultation with Dr. Miao Xiaohui for a range of reasons that reflect both the clinical depth of his expertise and the practical advantages of accessing infectious disease and hepatology care at Changhai Hospital.
For patients with chronic hepatitis B or C who have not been treated or whose treatment has been suboptimal, Dr. Miao's expertise in the latest antiviral therapies — including pan-genotypic DAA regimens for hepatitis C with cure rates exceeding 95%, and the newest nucleos(t)ide analogues for hepatitis B with the highest barrier to resistance — provides access to treatment that may not be available or affordable in their home countries. The cost of DAA therapy for hepatitis C at Changhai Hospital is substantially below that of equivalent treatment in Western healthcare systems, making curative hepatitis C treatment accessible to international patients who cannot afford treatment at home.
For patients with hepatitis-related cirrhosis and its complications, Dr. Miao's integrated approach — combining antiviral therapy to halt disease progression with active management of cirrhosis complications and coordination with hepatobiliary surgery and gastroenterology for advanced interventions — provides a comprehensive, multidisciplinary standard of care that is difficult to access outside major academic hepatology centers.
For expatriates living in Shanghai who require ongoing management of chronic hepatitis or liver disease, Dr. Miao and Changhai Hospital's infectious disease department offer continuity of specialist care with access to the full range of antiviral therapies, non-invasive fibrosis monitoring, and complication surveillance that optimal hepatitis management requires.
What to Expect at Your Consultation
Consultations with Dr. Miao Xiaohui at Changhai Hospital arranged through CMCS begin with a comprehensive review of all prior hepatitis and liver disease records — including viral serology (HBsAg, HBeAg, anti-HBe, anti-HBs, anti-HCV, HCV RNA, HBV DNA), liver function tests and bilirubin trend, complete blood count and platelet count, coagulation studies, alpha-fetoprotein, liver imaging (ultrasound, CT, MRI), prior liver biopsy or FibroScan results, and prior antiviral treatment history — as well as the patient's hepatitis history, symptom status, and relevant comorbidities. CMCS will arrange certified translation of all medical records and investigation results in advance of the consultation.
Dr. Miao will assess the hepatitis disease status and stage, evaluate treatment indication and optimal antiviral regimen, outline the recommended management plan including antiviral therapy, monitoring schedule, and complication surveillance, and coordinate multidisciplinary input from hepatobiliary surgery, gastroenterology, and oncology where appropriate. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Miao's team and the patient's home hepatologist or gastroenterologist for continuity of care.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking infectious disease and hepatology consultation with Dr. Miao Xiaohui at Changhai Hospital. Our services include priority consultation scheduling, certified medical record and laboratory result translation, coordination of FibroScan and liver imaging, on-site interpretation throughout the consultation, antiviral therapy coordination and pharmacy support, and written English-language reporting of all findings and recommendations. CMCS will also facilitate direct communication between Dr. Miao's team and the patient's home physicians to ensure seamless continuity of care.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 commenti